Yihui Zheng

As a bridge between early discovery and CMC — enabling drug developability assessment to guide lead molecule selection and optimization, inform CMC functions on key molecular attributes, and de-risk process development and manufacturing.

● Developability assessment for biosimilar or innovative drugs by structure biology methods (like structure modeling, protein-ligand/protein docking, physicochemical properties prediction). ● Optimization for antibody sequence during the phase of drug discovery, avoiding key PTM sites or SAP sites which will have a significant effect on aggregation or fragmentization issues in CMC state. ● DP development. To optimize drug formulation by high throughput screening experiments, from different perspectives (colloid stability, conformational tability, purity or accelerated thermostability).